BioHarvest Sciences Inc. Common Stock (BHST) Research

BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.

Market snapshot

Symbol
BHST
Price
$3.26
Day change
-0.61%
Market cap
$56.5M
P/E ratio
-6.46x
52-week range
3.02-12.8
Sector
Basic Materials
Industry
Agricultural Inputs
Next earnings
in 2 months
Analyst price target
$10.00

Recent news

  • BioHarvest Sciences and Tate & Lyle expand sweetener development program

    BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration with Tate & Lyle PLC (LSE:TATE) to broaden the scope of their joint sweetener development program to include multiple plant-based sweetener molecules. The expanded partnership builds on an agreement signed in 2024 and follows what the companies described as strong technical progress in developing sweetening solutions for food and beverage manufacturers.

  • BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline

    BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness business. The company posted first quarter revenue of $8.5 million, up from $7.9 million a year earlier, while maintaining its full-year revenue guidance range of $42 million to $48 million.

  • BioHarvest Sciences advances synthetic saffron program with SaffronTech partnership

    BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said that it has completed the first stage of a multi-stage development agreement with SaffronTech, establishing a stable saffron cell bank that the company says could one day offer a sustainable alternative to one of the world's most expensive agricultural commodities. The Nasdaq-listed biotech said completion of Stage 1 has triggered the start of Stage 2 under the ongoing agreement, which will focus on using its patented Botanical Synthesis platform to generate enough biomass to support pre-commercial testing and product development for nutraceutical and culinary applications.

Peer companies

  • Ascent Industries Co. (ACNT)
  • American Vanguard Corporation (AVD)
  • Bioceres Crop Solutions Corp. (BIOX)
  • Core Molding Technologies, Inc. (CMT)
  • FutureFuel Corp. (FF)
  • Friedman Industries, Incorporated (FRD)
  • Lavoro Limited (LVRO)
  • Mercer International Inc. (MERC)

Open BioHarvest Sciences Inc. Common Stock (BHST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.